Squenom !! NICHT verkaufen !! News :) - 500 Beiträge pro Seite

[moon2]

Jetzt noch zu Kursen zu 44 Euro kaufen.


Haben die Deutschen folgende Meldung noch nicht registriert?



Tuesday April 11, 6:30 am Eastern Time
Company Press Release
SOURCE: SEQUENOM, Inc.
SEQUENOM Announces Research Collaboration Agreement With Gemini Genomics to Discover SNP Disease Associations
SAN DIEGO, April 11 /PRNewswire/ -- SEQUENOM, Inc. (Nasdaq: SQNM - news) today announced a research collaboration agreement with Gemini Genomics plc to discover and validate associations between single nucleotide polymorphisms (SNPs) in the human genome and particular diseases, including disease risk traits. SNPs are the most common form of genetic variation and represent the origin of most differences between individuals.

``The challenge in today`s dynamic genomics environment is actually translating the enormous amount of collected data into relevant, useful information,`` said Hubert Koster, Ph.D., SEQUENOM`s President and CEO. ``This collaboration with Gemini signifies the next step beyond the discovery of genetic variations by employing our innovative marker compression strategy. Until now, methods of sheer force have been used to decode more than three billion base pairs in the human genome. However, in order to sort the fraction of meaningful variations from the several millions that exist requires the comparison of these SNPs between thousands of diseased and healthy individuals. Traditional methods would fail because they are simply too slow and inaccurate. We have solved this problem with an accelerated and more effective approach, which applies highly effective filters enabled by our MassARRAY(TM) system.``

According to the two-year agreement, Gemini will provide well-characterized DNA samples and clinical information for selected disease traits to be analyzed. The automated assay design and validation of these samples, including SNPs from the public domain, will be conducted using SEQUENOM`s highly accurate, high throughput and cost-effective MassARRAY system.

Upon completion of the sample analyses, SEQUENOM and Gemini will work together to analyze the data, attempting to identify and validate the medical relevance of particular SNPs associated with specific diseases or disease risk traits. Both companies will jointly commercialize any diagnostic or therapeutic applications resulting from the collaboration.

``We are pleased to have formed an alliance of this magnitude,`` said Dr. Paul Kelly, Gemini`s Chief Executive Officer. ``The potential benefits of combining SEQUENOM`s large-scale genotyping capabilities with our unique approach to clinical genetics are very exciting. The results from this collaboration will likely play an immediate and dramatic role in diagnostic targets for disease and in the development of causal therapies.``

Gemini is a unique genomics company focused on the discovery of novel gene based targets that offer maximum potential for the development of therapeutics or diagnostics by the pharmaceutical and health care industries. Gemini`s approach integrates comprehensive clinical data and detailed genetic information from a wide range of human population groups, including twins, disease affected families, isolated (founder) populations and drug trial subjects. By investing in leading edge bioinformatics technologies, Gemini is able to effectively apply these resources to the acceleration of disease gene identification, target discovery and drug development.

SEQUENOM is a pioneer in the new field of Industrial Genomics, the large-scale commercial use of the understanding of DNA variations for improving health and agriculture. The Company`s MassARRAY system represents a novel approach to genotyping by combining its proprietary enzymology, bioinformatics and a miniaturized chip-based format with the proven technology of mass spectrometry. The result is a highly accurate, cost-effective technology that addresses the demand for high throughput SNP analysis and can be rapidly reconfigured for different types of analyses. SEQUENOM is headquartered in San Diego, Calif. with offices in Hamburg, Germany and Boston, Mass.

Except for the historical information contained herein, the matters discussed in this press release may contain forward-looking statements which involve risks and uncertainties, dependent upon, for example, uncertain or fluctuating customer requirements, uncertain or fluctuating market demand and acceptance, fluctuations in product performance, dependence on the efforts of third parties, a new and uncertain technology employed by SEQUENOM and its uncertain application to new business ventures and the needs of individual customers, dependence on intellectual property rights, the competitive nature of SEQUENOM`s industry and risks of obsolescence of certain technology. Actual results may differ materially from those, to the extent projected herein, if at all. To the extent forward-looking statements are contained herein, they represent the judgment of SEQUENOM as of the date of this release. SEQUENOM disclaims, however, any intent or obligation to update any forward-looking statements.

SOURCE: SEQUENOM, Inc.

[Capt.Janeway]

Leider kann ich nicht so gut English,

kannst Du eine kurze Zusammenfassung auf Dt. reinschreiben ??

Wäre sehr nett !!!

Grüße aus dem Delta Quadranten!!!!

[moon2]

Ich sag nur riesige Übertreibung nach unten.

Oder Sell on good News ?

TUESDAY, APRIL 11, 2000 2:43 PM
- Reuters


LONDON, April 11 (Reuters) - Privately-owned British biotech company Gemini Genomics, expected to be floated soon on the Nasdaq stock exhange, announced a collaboration with Sequenom Inc (NASDAQ:SQNM) on Tuesday to search through data of the Human Genome Project.

The two companies would study genetic variations, find relevance behind select diseases and eventually come up with drug targets for pharmaceutical companies.

Gemini, which has done some extensive studies on twins, will bring its diverse human population resources while Sequenom will use its DNA genotyping abilities.

Both firms will study genetic variations linked to some common chronic diseases like diabetes, osteoporosis and obesity.